68-2

13/110

(98.8%)(97.4%)(97.9%)(4.7%)cations have reduced from 3-4% in the 1990s to 1%. Since the introduction of OPCAB, there have been fewer infections, higher blood transfusion rates (70%), and shorter hospital stays (Table 2). In the diabetic group, the 10-year overall survival rate was 67%, and the cardiac death-free rate was 78%, which was worse than the non-diabetic groups with rates of 74% and 83%, respectively (Figure 5). Regarding preoperative renal function, all-cause mortality, cardiac mortality avoidance rate, and No. of patientsOPCABMIDCABEmergency(<24hrs)No. of anastomosisOnly SVGNo. of arterial graft 1 2 3 ≥4No. of patients; Number of patients. OPCAB: Off-pump coronary artery bypass grafting. MIDCAB: Minimally invasive coronary artery bypass grafting. No of anastomoses: Number of anastomosesOnly SVG: Only saphenous vein graft. No. of arterial grafts: Number of arterial graftsFigure 4　Primary isolated coronary artery bypass grafting at Juntendo UniversityChanges of preoperative patients` baselineCVA: cerebrovascular accident, HD; hemodialysis, CKD: chronic kidney disease, DM: Diabetes MellitusTable 1　Changes in the number of primary isolated coronary artery bypass grafting at Juntendo University1984-19891990-1995787785000005812(1.5%)2.4 ± 0.816(2.0%)2.5 ± 0.851327200067625001996-20016883227(3.9%)2.7 ± 0.8841449318010major adverse cardiovascular events (MACE), outcomes all worsened from CKD stages G1 to G5. The 10-year survival rate for G1 was 84%, but 32% for G5, and long-term outcomes worsened as renal function declined, with 85% for G1 and 49% for G5 MACE (Figure 6). In a meta-analysis of all-cause mortality, the independent risk factors were preop-erative dyslipidemia, diabetes mellitus, peripheral vascular disease, previous stroke, dialysis, and low left ventricular function (Table 3). For MACE, the 2002-20072008-2012931912950950671588(9.8%)3.6 ± 1.453(5.9%)3.4 ± 1.31622322213111643242711832013-20209029022459(5.9%)3.3 ± 1.267201269219206105